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Neuroendocrine differentiation (NED) marks a structural and functional feature of certain
cancers, including prostate cancer (PCa), whereby the malignant tissue contains a sig-
nificant proportion of cells displaying neuronal, endocrine, or mixed features. NED cells
produce, and can secrete, a cocktail of mediators commonly encountered in the nervous
system, which may stimulate and coordinate cancer growth. In PCa, NED appears during
advanced stages, subsequent to treatment, and accompanies treatment resistance and
poor prognosis. However, the term “neuroendocrine” in this context is intrinsically vague.
This article seeks to provide a framework on which a unified view of NED might emerge.
First, we review the mutually beneficial interplay between PCa and neural structures, mainly
supported by cell biology experiments and neurological conditions. Next, we address the
correlations between PCa and neural functions, as described in the literature. Based upon
the integration of clinical and basic observations, we suggest that it is legitimate to seek
for true neural differentiation, or neuromimicry, in cancer progression, most notably in PCa
cells exhibiting what is commonly described as NED.
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NEUROENDOCRINE DIFFERENTIATION: OLD CONCEPT,
NORMAL COUNTERPARTS, VAGUE TERMINOLOGY
Neuroendocrine differentiation (NED) is a term referring to cer-
tain cancers that display a prominent neuroendocrine (NE) cell
population on histopathologic examination. Although the defini-
tion has been used primarily in relation to prostate cancer (PCa),
it is by no means restrictive [see, e.g., Ref. (1)]. NE cells display a
combination of neuronal and endocrine features, best described
as a partly neuron-like morphology and an endocrine-like secre-
tory mechanism (see below). The whole NE concept itself had
nothing to do with cancer; it arose in the late 1920s, when it was
discovered that some hypothalamic neurons secrete their products
into the bloodstream rather than into a specialized synaptic cleft as
well described by Montuenga and colleagues (2). Subsequently, the
existence of hybrid, neuronal-endocrine cell type, NE, was widely
accepted.
Abbreviations: ADT, androgen deprivation therapy; AR, androgen receptor; BPH,
benign prostatic hyperplasia; CgA, chromogranin A; CR, castrate resistance; CSC,
cancer stem cells; DAD-1, defender against apoptotic cell death 1; EPSCC, extra-
pulmonary small cell carcinoma; GA, general anesthesia; IL, interleukin; JAK,
Janus kinase; MAPK, mitogen-activated protein kinase; NAA, neuraxial anesthe-
sia/analgesia; NE, neuroendocrine; NED, neuroendocrine differentiation; NF-κB,
nuclear factor kappa B; NK, natural killer; NSE, neuron-specific enolase; PCa,
prostate cancer; PI3K, phosphoinositide 3-kinase; PIM-2, provirus integration of
Moloney virus 2; PKA, protein kinase A; SCCP, small cell carcinoma of the prostate;
SCLC, small cell lung carcinoma; SCI, spinal cord injury; STAT, signal transducer
and activator of transcription; VEGF, vascular endothelial growth factor.
Although the NED term relates to malignant tumors enriched
in a NE cell fraction, NE cells are not ominous per se, but are part of
a large cell population, collectively known as the diffuse NE system,
which is dispersed throughout the normal organism. The NE cells
primarily exist within the organs that interface with the outside
world, including gastrointestinal, respiratory, and genitourinary
systems, as well as the skin (Merkel cells and melanocytes). Yet,
they also can be found within endocrine glands or tissues, such as
the hypothalamus, anterior pituitary, pineal gland, thyroid gland
(calcitonin-secreting cells), thymus, breast, and the pancreatic
islets of Langerhans [reviewed in Ref. (2–4)]. For terminology
clarification, we note that usually the term “NE” refers to both
cancerous and non-cancer-related cells, while the term “NED”
(with a “D”) refers specifically to cancerous cells. A cocktail of
terms have been used interchangeably throughout the literature
over the last century (e.g., APUD cells, endocrine/paracrine cells).
This ambiguity arises from the visualization techniques used and
the norms around the time of publication (2). This lack of stan-
dard nomenclature makes NE-related literature search particularly
challenging, as some articles containing important findings can be
missed.
In the healthy organism, normal NE cells play complex local
regulatory roles at the tissue level. For example, the NE cells of
the gastrointestinal tract (also known as enteroendocrine cells)
regulate secretion, motility, as well as cell growth and differenti-
ation in the gut. For this purpose, these cells employ endocrine,
autocrine, paracrine, and neurocrine signaling mechanisms, and
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are, in turn, under neural control (5). The NE cells of the respira-
tory tract can control lung branching morphogenesis, cell growth
and maturation during development, and it is believed that they
provide a protective niche for a subset of lung stem cells. Similarly
to enteroendocrine cells, pulmonary NE cells are under control of
a complex innervation [reviewed in Ref. (4)].
NEUROENDOCRINE CELLS IN THE NORMAL PROSTATE
Neuroendocrine cells are normal inhabitants of the human
prostate, existing in all areas of the gland, including prostate ducts,
acinar epithelium, and prostatic urothelium, but they localize
preferentially in the major ducts [reviewed in Ref. (3, 6)]. Pro-
static NE cells are found in lower numbers in African-American
males, who are more prone to developing PCa; NE cells thus
might have a protective role against prostatic carcinogenesis (7).
As with all NE cells, the NE prostatic cells usually cannot be rec-
ognized under the light microscope using conventional staining
techniques, but can be readily traced immunohistochemically by
staining for the specific markers chromogranin A (CgA), synap-
tophysin, or neuron-specific enolase (NSE). In some cases, one or
more NE markers may be absent [reviewed in Ref. (8)].
Prostatic NE cells share the morphological and ultrastructural
features of NE cells from other parts of the body [reviewed in-
depth in Ref. (2); also reviewed in Ref. (4, 5)]. Under the electron
microscope, two different morphologies were described. The open-
type cells display thin apical processes that extend luminally, reach
the lumen, and possess long surface microvilli. The closed-type
cells have dendritic-like processes that extend between adjacent
epithelial cells, but do not reach the lumen. The closed-type cells
are surrounded by epithelial cells. Although no study has specif-
ically addressed this question for the prostate, it is assumed that
this morphological classification also has an important functional
significance. Closed cells can only receive basal stimuli (neuro-
transmitters from nerve endings, hormones from neighboring
blood vessels, local paracrine, or autocrine factors from underly-
ing stromal cells). By contrast, open cells also can receive luminal
stimuli (pH, chemicals). It is therefore generally believed that the
open and closed NE cell populations, irrespective of their specific
location, are functionally different [reviewed in Ref. (2)].
The NE cells of the prostate contain secretory granules whose
electron microscope features allow further classification [reviewed
in Ref. (3, 8)]. The contents of the secretory granules display a
remarkable diversity and belong to the family of neuromedia-
tors that are used for signaling throughout the nervous system.
Apart from three NE markers CgA, synaptophysin and NSE, NE
cells synthesize other members of the chromogranin family as
well as a variety of hormone-related substances, including chro-
mogranin B and chromogranin C (secretogranin II); serotonin;
histamine; thyroid-stimulating hormone-like peptide; calcitonin
and related peptides (calcitonin gene-related peptide, katacal-
cin); α-human chorionic gonadotropin; somatostatin; bombesin;
parathyroid hormone-related protein; vasoactive intestinal pep-
tide; neuropeptide Y; cholecystokinin; vascular endothelial growth
factor (VEGF); glucagon; β-endorphin; Leu-enkephalin; and
adrenomedullin [reviewed in Ref. (2, 3, 6, 8, 9)]. It remains unclear
if a single NE prostatic cell can synthesize this huge cocktail, or a
vast majority, or only a subset thereof. Regarding the diffuse NE
system, it is known that, in principle, single NE cells can produce
more than one hormone-related substance [reviewed in Ref. (2)].
Some prostatic NE cells were reported to produce two mediators
instead of one, and it is apparent that several subpopulations of
NE cells exist in the prostate, each of them producing a specific
subset of mediators (10). Receptors for some of these neurome-
diators were described in benign prostatic tissue and/or in PCa
and include receptors for serotonin, calcitonin, bombesin, somato-
statin, cholecystokinin, neuropeptide Y, and neurotensin [Ref. (11,
12); see also Ref. (8) and the references therein].
Although NE cells were first described in the normal prostate
60 years ago [Grasso, 1954, cited in Ref. (13)], few studies have
addressed their function. Do normal prostatic NE cells actually
secrete all those compounds they synthesize? Do they regulate
other cells and if they do, then what are the regulatory mecha-
nisms? What exact role(s) does each of those compounds have in
the prostate, if secreted? These are all questions that remain to
be addressed, as most of the data available come from extrapola-
tion. For example, CgA, which is one of the most prominent NE
markers, regulates the secretory vesicle pool and calcium home-
ostasis, and it accompanies catecholamines in the secretory vesicles
in the sympathetic and adrenomedullary systems [reviewed in
Ref. (14)], but there is considerably less evidence as to its specific
roles in the prostate. Similarly, the roles of the other neuropep-
tides are incompletely understood. However, the neuropeptides
influence depolarization, modulate ionic currents, release calcium
from intracellular stores, stimulate ATP synthesis, stimulate oxida-
tive phosphorylation, and regulate mRNA transcription. Globally,
prostatic NE cells are thought to play a key role in prostate growth
and differentiation [reviewed in Ref. (15)].
In early descriptions, prostatic NE cells displayed heteroge-
neous cytokeratin expression (a classification into basal, luminal,
and intermediate NE cell types is based on this criterion) [reviewed
in Ref. (16)]. More recent accounts indicate that prostatic NE cells
express K5 cytokeratin, which is a basal cell marker [reviewed
in Ref. (8)]. NE cells appear to be non-proliferative, postmitotic,
as they lack the proliferation marker Ki-67. They, however, lie
preferentially adjacent to proliferating and Bcl-2-positive cells,
a pattern suggesting that NE cells support the growth of non-
NE cells through paracrine mechanisms [Ref. (15, 17, 18); also
reviewed in Ref. (2)]. However, most proliferating non-NE cells do
not lie close to NE cells (17), which makes this relationship harder
to rationalize. Another prominent feature of these cells is the lack
of androgen receptor (AR) [Ref. (19); also see Ref. (6, 16, 20) and
the references therein]. This is particularly intriguing,as androgens
are considered to be the most important growth-supporting factor
in the prostate, with innervation being the second most important
(21). In animal models, NE cell number and morphology are not
influenced by castration or prostatic denervation (22). In fact, it
remains unclear which factors account for the regulatory control
of NE prostatic cells, or if these regulatory signals are endocrine,
paracrine, autocrine, neurocrine, or “lumencrine” (i.e., signals in
the duct lumen itself) (23).
The developmental origin of these cells long has been a matter
of debate. Normal prostatic NE cells likely share a common devel-
opmental origin with urogenital sinus-derived luminal and basal
cells. A second lineage was identified that has a neurogenic origin
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from periprostatic paraganglia (24). Consequently, some authors
have proposed that these cells have a neurogenic origin, arising
from the paraganglia that flank the urogenital mesenchyme; by
subsequent migration, these precursor cells populate the prostatic
epithelium. Other authors have suggested that prostatic NE cells
have a local prostatic origin, arising through differentiation of a
local pluripotent stem cell that gives rise to all the epithelial cell
types in the prostate [Ref. (20); also reviewed in Ref. (2)]. Recent
work leans to the local prostatic origin hypothesis. During devel-
opment, postnatal development, as well as in the adult organism,
the prostatic NE, luminal, and basal cells arise through differen-
tiation of local multipotent stem cells expressing the p63 protein
marker (25–27).
NEUROENDOCRINE DIFFERENTIATION IN PROSTATE
CANCER: SEPARATE CATEGORIES VS. CONTINUUM
In the context of prostatic malignancy, NED is a highly heteroge-
neous phenomenon. From a spatial viewpoint, there are (i) tumors
that are purely NE, such as small cell carcinoma of the prostate
(SCCP), carcinoid, and carcinoid-like tumors, or (ii) tumors that
are non-NE (e.g., adenocarcinomas) but exhibit rather focal NE
features (in primary and/or metastatic sites). These can be further
divided with respect to timing: some adenocarcinomas display
large populations of NE cells from the start, while others recur
as NE carcinoma later on [reviewed in Ref. (3, 28)]. Some points
of this categorization remain debatable [e.g., more recent studies
of NED have deliberately excluded carcinoid and carcinoid-like
tumors as belonging to a different histological category, while oth-
ers (29) have considered them as NED tumors]. The classification,
however, emphasizes two important elements. First, the extent of
NED varies across patients, in that some tumors exhibit focal NED
(i.e., only a subpopulation of tumor cells exhibit NE features)
(Figure 1) while others display universal (pure) NED (i.e., the
tumor is entirely composed of NE cells). The universal NED is, in
fact, SCCP, which accounts for 1% of the prostatic malignancies
and, similarly to small cell carcinomas from other organ sites, has
a particularly poor prognosis (30) (Figure 2). Second, the tim-
ing of NED varies across patients, in that certain patients show
NED tumors from the beginning, while others receive treatment
for conventional PCa and later experience recurrence with NED
tumors.
An important question to be asked is, therefore, if the NED
categories described above are discrete phenotypes or if they rep-
resent a continuum of phenotypes. First, it is known that some
histological and immunohistochemical traits are common to con-
ventional prostatic adenocarcinoma and SCCP (31). Second, there
is a growing body of literature reporting therapy-associated pro-
gression from (i) conventional prostatic adenocarcinoma to focal
NED, (ii) focal NED to SCCP, or (iii) conventional prostatic adeno-
carcinoma to SCCP (32–40). Progression to these NED categories
occurred in any stage of the disease (i.e., organ-confined, locally
advanced, metastatic) (32–34, 36–39). Third, increasing evidence
shows cases of mixed adenocarcinoma/SCCP tumors. In these
patients, disease stage correlates directly, while survival correlates
inversely, with the proportion of the SCCP fraction and the grade
of the associated adenocarcinoma fraction (30), suggesting that
PCa gains in relative SCCP proportion as the disease progresses.
FIGURE 1 | Prostate cancer displaying focal neuroendocrine
differentiation. Focal NED typically requires specific staining methods.
However, in about 10% of cases, NE cells display large eosinophilic
granules recognizable by conventional staining (arrows). In focal NED, the
NE cells occur either as solitary cells or in clusters. H&E stain. Courtesy
and with permission of Dharam M. Ramnani, MD; WebPathology.com.
FIGURE 2 | Prostate cancer displaying universal neuroendocrine
differentiation. Universal NED is synonymous to SCCP. This cancer type is
rarer than conventional prostatic adenocarcinoma (fewer than 1% of total
PCa cases) and prognosis is dismal. Histologically, cells display scarce
cytoplasm, hyperchromatic nuclei with finely dispersed chromatin and
inconspicuous nucleoli, and nuclear molding. Mitotic index is high and
necrosis often is present. In about half of the cases, the small cell
carcinoma is admixed with areas of conventional prostatic adenocarcinoma.
The Gleason scale cannot be used for pure SCCP, but in mixed cases it
should be used to grade the adenocarcinoma regions. H&E stain. Courtesy
and with permission of Dharam M. Ramnani, MD; WebPathology.com.
SCCP might, in fact, represent the least differentiated type of con-
ventional prostate adenocarcinoma (i.e., beyond the Gleason 10
score), which would indicate adenocarcinoma and SCCP form a
continuum (30).
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Collectively, these data strongly suggest that (i) NED in PCa is
a dynamic and continuous range, spanning from conventional
adenocarcinoma to SCCP; (ii) progression across this range is
directed from conventional adenocarcinoma to SCCP; (iii) pro-
gression can occur at any stage of the disease; and (iv) progression
is driven by therapy (Figure 3).
Last, it is worth mentioning that a new classification of NED
has been proposed recently (29), in which the extent and timing
of NED have been abandoned and NED is categorized solely on
morphologic observations. As the authors themselves acknowl-
edge, apart from the purely histopathologic perspective, most of
the new categories proposed bear little clinical significance (29).
Based on the existing literature discussed above, we suggest that the
present classification should be kept in place, and refined only as
the full genotypic and phenotypic character of NED is discovered.
NEUROENDOCRINE CELLS IN PROSTATE CANCER
Neuroendocrine cells first were reported in malignant prostate tis-
sue almost 45 years ago (41), making it the first description of NED
FIGURE 3 | Neuroendocrine differentiation spans a continuous and
dynamic range. Conventional prostatic adenocarcinoma, focal NED, and
SCCP traditionally are represented as separate entities, but evidence
shows that they rather form a unique spectrum of prostatic malignancies.
The common denominator encompasses two parameters: the extent of
NED (green gradient), spanning from zero (conventional prostatic
adenocarcinoma) to universal NED (SCCP), and the extent of malignant
dissemination (red gradient), ranging from localized to metastatic disease.
During first presentation or reoccurrence, NED can be diagnosed at any
point across this plane (black human icons). For any patient, any parameter
can shift to a higher value at any stage during the course of the disease
(see color-coded arrows, each color corresponding to one patient), but no
parameter shifts to a lower value (gray arrows crossed by red saltires). Loc,
localized disease; Met, metastatic disease; ADK, conventional prostatic
adenocarcinoma; NED, focal NED; SCCP, small cell carcinoma of the
prostate.
in PCa. Similarly to normal NE cells, the NE tumor cells express
various neuromediators (see below).
It is important to unravel the phenotypic and genotypic asso-
ciations between normal and tumor-associated NE cells. Surpris-
ingly, NE tumor cells are in many ways indistinguishable from their
adjacent, conventional non-NE tumor counterparts (42). First,
NE tumor cells express K18 and K8 cytokeratins, which also are
expressed by luminal cells of the prostatic epithelium and also
by conventional tumor cells (i.e., adenocarcinoma cells). How-
ever, they do not express high-molecular weight cytokeratin and
p63, which are associated to the basal cells of the prostatic epithe-
lium (43, 44). By contrast, normal NE cells mainly express K5,
a basal cell marker (see above). Second, both NE tumor cells and
non-NE tumor cells express theβ-oxidation enzymeα-methylacyl-
CoA-racemase (AMACR) (43), a recently identified marker that is
strongly associated with PCa risk (45). By contrast, normal NE
cells lack this marker (43). Third, genetic analysis revealed that
NE tumor cells are similar to non-NE tumor cells rather than to
NE normal cells. The NE normal cells, in turn, are similar to the
non-NE normal cells (46). It is thus apparent that belonging to the
malignant vs. benign prostatic phenotype is a stronger clustering
factor than belonging to the NE vs. non-NE cell type.
Similarly to NE cells in the normal and hyperplastic prostate
tissue, NE tumor cells are non-proliferative, postmitotic cells (17,
18, 43, 44), and they lack stem-like cell markers ALDH1, NANOG,
and CD44 (44). They are mainly adjacent to proliferating (17, 43)
and Bcl-2-positive cells [see Ref. (16) and the references therein],
and such NED areas exhibit the highest proliferation index across
the tumor tissue (47). It is therefore not surprising that, the more
NED areas a tumor displays, the higher the proliferation index
at the global tumor level; that is, the extent of NED correlates
with higher proliferation index of the whole tumor [Ref. (47),
although see Ref. (17)]. The NE tumor cell density per NED area
further enhances proliferation. Proliferation index among NE cells
is higher in tumors displaying clusters of NE cells as compared to
tumors displaying solitary NE cells or no NE cells (47).
How are NE tumor cell signals broadcast, though? In mice,
androgen-dependent LNCaP prostate tumors can grow in castrate
conditions only in the presence of NE tumors, which suggests that
NE tumor cells secrete some long-range, endocrine factors (48).
However, the effect is not seen in vitro, as conditioned medium
from NE tumor cells does not rescue decreased growth of LNCaP
cells in androgen-depleted conditions (48). Although this differ-
ence between in vivo and in vitro could be attributed to a different
gene expression profile of LNCaP and/or NE cells, it also could
be accounted for by the absence of NE cells in the in vitro exper-
iments. Namely, it is possible that short-range, paracrine factors
[as hypothesized more than two decades ago (17)], or direct cell–
cell contact are responsible for the NE tumor cell supportive role.
Indeed, LNCaP cells proliferate more than twofold faster when
co-cultured with LNCaP cells displaying NED (49), which further
supports this view.
It is commonly accepted that NE tumor cells are AR- and PSA-
negative and prostatic acid phosphatase-positive [Ref. (43, 44), see
also Ref. (50) and the references therein]. Older studies suggest
that a small minority of NE tumor cells display some AR expres-
sion (19). The lack of AR makes them androgen-independent, as
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are NE normal cells. In an in vivo model of human PCa xenograft
subjected to androgen deprivation (castration), the residual tumor
is enriched in NE tumor cells, which appear to result by selection,
i.e., survival, despite the lack of androgens (44).
Regarding the origin of NE tumor cells, it has been suggested
that PCa NE cells share a common intermediate stem cell ori-
gin with their normal NE counterparts. Others hypothesized that
since normal NE cells do not proliferate, PCa NE cells are likely to
arise through transdifferentiation from either conventional pro-
static adenocarcinoma cells or prostatic exocrine cells becoming
malignant [Ref. (18); also reviewed in Ref. (8)]. The stronger
genetic clustering of tumor NE/non-NE cells as compared to
tumor NE/normal NE cells lends further support to the second
hypothesis (46).
Interestingly, not all NE cells found in PCa are genuine NE
tumor cells. Sion-Vardy’s group described a CgA- and serotonin-
expressing NE cell population in the normal peritumoral regions
(10). By contrast, other NE markers (NSE and adrenomedullin)
were expressed uniformly across normal peritumoral and tumoral
regions, and across PCa and benign prostate hyperplasia patients,
respectively, which suggests that the prostate may contain several
different NE cell populations (10). It might be that PCa induces
neighboring benign cells to transdifferentiate into NE cells, which
then promotes tumor growth through their secretory products
(10). Neuropeptides of NE cells promote tumor growth in vitro
(51), but the functions of various mediators have only begun to be
unraveled.
It is particularly intriguing that not all tumor-produced neu-
romediators are uniformly tumor-supportive. For instance, CgA,
which is among the most prominent NED markers, displays com-
peting activities. CgA is active in its full-length form, but it is also
physiologically cleaved at various sites, generating about a dozen
of bioactive fragments [reviewed in Ref. (14)]. These hormones
play intricate regulatory roles in vascular and tumoral biology,
either as pro-angiogenic or anti-angiogenic factors [reviewed in
Ref. (52)]. Vasostatin-1, one of the most widely studied CgA frag-
ments, inhibits tumor angiogenesis, apparently by inhibiting the
endothelium-stimulatory effects of hypoxia and tumor-secreted
factors. This, in turn, precludes the activation of endothelial cells
and preserves the integrity of the endothelial barrier. At the mol-
ecular scale, vasostatin-1 inhibits hypoxia-driven nuclear translo-
cation of HIF-1α (53). By contrast, full-length CgA has a biphasic
effect. While physiologic concentrations inhibit both spontaneous
and VEGF- and FGF-2-induced angiogenesis, the anti-angiogenic
effect is lost at supraphysiologic CgA concentrations, suggesting
that high CgA levels, as occur in NE and some non-NE cancers,
might reduce the anti-angiogenic effect (54). Moreover, thrombin
provides an angiogenic switch characterized by gradual cleavage-
induced inactivation of anti-angiogenic fragments of CgA, cou-
pled to cleavage-induced generation of pro-angiogenic fragments
of CgA. This switch is relevant in clinical conditions exhibiting
thrombin activation, including cancer (54), a hallmark of which
is angiogenesis [reviewed in Ref. (55, 56)]. CgA and CgA-derived
hormones also play opposing roles in regulating tumor prolif-
eration. In mice, CgA inhibits transit of mammary cancer cells
among primary tumor, blood, and organ compartments (57).
Mechanistically, CgA inhibits tumor cell-induced formation of
endothelial gaps and decreases TNFα-induced vascular leakage
(58), reduces vascular leakage within tumors, and inhibits tumor
cell transendothelial migration (57). However, vasostatin-1 and -2
stimulate proliferation in small intestinal NE metastatic cell lines
via Akt phosphorylation, although they do not affect small intesti-
nal NE primary tumor cell lines (59). In PCa cell lines, various
CgA fragments have opposing roles, as some stimulate, while oth-
ers inhibit invasion, haptotactic migration, and growth [see Ref.
(60) and the references therein]. It becomes thus apparent that
factors produced by NE tumors can exert effects of both polarities,
either enhancing or diminishing tumor development.
INDUCERS OF NEUROENDOCRINE DIFFERENTIATION
Numerous molecular signals and pathways connect to NED,
or to functional features commonly associated with it, such as
androgen-independent growth. These consist of (i) ligands that
induce NED or NED-related features, and (ii) signals generated
by NE cells that affect tumor dynamics. The distinction between
the two categories is blurry, as some of the latter stimuli can
themselves induce NED. The entire repertoire of NED inducing
factors include neuromediators (bombesin, calcitonin, serotonin,
and vasoactive intestinal peptide) (11, 51, 61, 62), cytokines (IL-1β,
IL-6, and IL-8) (11, 63–75), ionizing radiation (76), elevated intra-
cellular cAMP [Ref. (77); also see Ref. (46) and references therein],
Wnt proteins (78), PI3K–Akt–mTOR pathway (79), and high-cell
density (80). NED also can be at least partially reversed, and the
extent of reversibility depends on the NED inducer (46, 76).
While NED transition can be induced by various cues, it mainly
results from androgen deprivation therapy (ADT) [Ref. (81); also
see cases documented in Ref. (32–36, 38, 39)], which is done by
pharmacological or surgical castration and is the standard of care
in advanced PCa (82). Because virtually all PCa cells rely on andro-
gens to grow, ADT can hold the disease at bay for a while, thus
increasing progression-free survival. However, nearly all patients
on ADT eventually develop androgen resistance (82), a term that,
although extensively used in the literature, is somewhat confus-
ing. The PCa cells develop the ability to grow in the absence of
androgens, but it is the androgen deprivation they become resis-
tant to, not the androgens themselves. Clearly stated, PCa cells
become androgen-independent, i.e., self-sufficient to androgen
growth signals, or ADT-resistant, which is a first hallmark of can-
cer (55, 56). In this text, we will use the synonymous term: castrate
resistance (CR).
In PCa, more aggressive ADT promotes more rapid NED transi-
tions [reviewed in Ref. (83)]. In mice, androgen depletion triggers
regression and NED within the primary tumor. The androgen
depletion-induced NED is proliferation-independent, and NE
tumor cells exhibit increased expression of serotonin, bombesin,
and somatostatin (16, 44). In patients with metastatic PCa, serum
CgA levels are associated with duration of ADT (84). Moreover,
CgA levels increased faster in patients with PSA failure than in
patients without it, suggesting that velocity of CgA increase might
help predict the risk of biochemical failure after ADT (84). The
rhythm of ADT administration might also play an important role
in NED dynamics. Sciarra’s group found that continuous ADT sig-
nificantly increased serum CgA in both localized and metastatic
PCa patients, whereas intermittent ADT did not influence serum
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CgA in either patient subset (85). Interestingly, AR expression did
not correlate with presence of NE cells or with biochemical recur-
rence, which is consistent with previous observations and suggests
that NE cells do not influence AR expression in neighboring cancer
cells (86).
Because ADT promotes both CR and NED, an important ques-
tion is if CR and NED go hand-in-hand and are causally linked?
Observations published to date make it hard to give a definite
answer. However, among patients who develop NED following
ADT, more than 80% developed CR at an intermediate point
between ADT initiation and NED (40), so at least a subset of
patients with CR will develop NED during their clinical course
(87). Although irrefutable evidence is still lacking, it is therefore
usually implied that the most common clinical sequence leading
to NED is:
Advanced conventional prostatic adenocarcinoma→
ADT initiation→ CR→ NED
It should be kept in mind, however, that the alternative sequence:
Advanced PCa displaying NED → ADT initiation→ CR,
in which NED precedes CR, also is encountered in the clinic.
If found in treatment-naïve patients, NED may predict a poor
response to ADT (see next section), in which case NED must have
occurred first. Moreover, as NED can develop at any stage of the
disease (Figure 3), still other clinical sequences also are possible.
CLINICAL SIGNIFICANCE OF NEUROENDOCRINE
DIFFERENTIATION IN PROSTATE CANCER
In PCa patients, NED is a frequent histopathological finding,
ranging from 31 to 100% of cases in primary tumors (9, 17,
42, 47, 86, 88–92), while occurring in 12% of metastatic lymph
node samples (90). It has been proposed that, in PCa, NED
cells appear in tissue regions that are similar to non-cancerous
atrophic glands (86). The most frequently expressed neuropep-
tide across tumor samples is calcitonin (37.1% of samples), fol-
lowed by neurotensin (11.4%), serotonin (10%), α-human chori-
onic gonadotropin (8.6%), vasoactive intestinal peptide (5.7%),
and bombesin (2.9%) (86). Using less restrictive criteria, others
reported NSE (77% of the samples) and CgA (59%) as the most
frequently expressed neuropeptides (9). However, significant vari-
ations were found in these studies with respect to the NED markers
used and the internal structure of the patient groups (most notably,
the clinical setting and the prior therapy). We note that while all
these immunohistochemical markers might be useful for diag-
nosing NED cancers, it is unclear if they also are useful for new
therapeutic strategies. Developing new therapies requires assess-
ing how efficiently a potential drug reaches its target. In addition,
since NED most often is a focal process, histopathologic markers
are less accurate than serum markers. On the other hand, serum
markers are expressed by prostatic non-NE cells as well; hence,
their levels depend on global prostatic tissue volume rather than
on specific NE cell number (93).
This chapter mainly discusses NED from a histopathological,
rather than a functional, standpoint. Therefore, we will follow
the nomenclature tradition of the existing body of literature.
Histopathologically, while focal NED is relatively frequent,
universal NED is a rare event (accounting for 1% of prostatic
malignancies). For this reason, focal NED is commonly referred
to as simply “NED,” while universal NED is usually referred to by
its well-known pathological term “SCCP.” For consistency, we will
follow this convention.
SCCP (UNIVERSAL NED) AND PROGNOSIS
Conventional prostatic adenocarcinoma, which accounts for the
vast majority of PCa cases, has an excellent prognosis due to its
slow clinical course and the available screening tests. By contrast,
SCCP is a fatal disease. In patients with SCCP, 2- and 5-year
survival rates are 27.5 and 14.3%, respectively, while median
survival is 15 months for locoregional disease and 7 months for
metastatic disease (30). Histopathologically, SCCP belongs to
a large family of cancers referred to as small cell carcinomas,
which share identical tissue architecture (small cells, round- or
spindle-shaped, displaying sparse cytoplasm, nuclear molding,
high-mitotic index,and frequent necrosis) that can be readily iden-
tified by conventional hematoxylin and eosin staining [reviewed
in Ref. (94–96)]. According to the site of origin, small cell carci-
nomas are conventionally divided into small cell lung carcinoma
(SCLC), the most frequent, and extrapulmonary small cell carcino-
mas (EPSCC), which include cancers from all other sites, including
SCCP. Although rare, EPSCCs have been documented in virtually
all organs in the body (94, 97–99), including the brain, which
had traditionally been considered not to display primary SCC
tumors (100). Despite this diversity of organ sites, EPSCC and
SCLC exhibit virtually identical patterns of behaviors: extremely
poor prognosis, quasi-identical therapeutic regimens, high- and
short-lived initial response to platinum agents, and topoisomerase
inhibitors, followed rapidly by tumor relapse and death, shared
molecular alterations, and similar histopathology (Figure 4). This
FIGURE 4 | Small cell carcinomas are a large, homogeneous family of
cancers. The histology, therapeutic regimens, response to therapy, and
prognosis of SCCP are strikingly similar to small cell carcinomas of all the
other organ sites, including SCLC shown here. Extensive nuclear molding
and apoptotic bodies can be seen. See Figure 2 for comparison with SCCP.
H&E stain. Courtesy and with permission of Dharam M. Ramnani, MD;
WebPathology.com.
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clinical, pathological, therapeutical, and prognostic pattern for
both EPSCC and SCLC has remained unchanged over the last
decades (94, 96, 98, 99, 101–106), and the only organ sites where
EPSCC displayed better prognosis are breast (99, 104) and female
reproductive tract (104), most notably the cervix (102, 105). How-
ever, the prognosis for breast SCC is poorer as compared to all other
types of non-inflammatory breast cancers combined (107). Like-
wise, the prognosis of cervical SCC is poorer than the prognosis
for squamous cell carcinoma and adenocarcinoma of the cervix,
respectively (105). Thus, even for these situations where EPSCC
breaks the rule and displays better outcomes, the relative progno-
sis is poorer compared to other cancers originating from the same
site, and the pattern is therefore preserved. Collectively, these data
strongly suggest that universal NED is a unique disease that dis-
plays a consistently homogeneous pattern of tumor behavior and
clinical outcomes irrespective of the organ site of origin.
NED (FOCAL NED) AND PROGNOSIS
After two decades of research, it is commonly perceived that NED
in PCa indicates poor prognosis. This impression could be due to
a mere association, as NED correlates with tumor grade [reviewed
in Ref. (3); see below]. Thus, it might not be NED itself, but the
high tumor grade it accompanies, which accounts for the poor
prognosis. Alternatively, this could be a true causative relation-
ship, in which the NE tumor cells themselves generate a resistance
to hormonal therapy. This idea is consistent with repeated find-
ings that PCa that exhibit NED are hormone-resistant [reviewed
in Ref. (3); also see below], as well as with the fact that adeno-
carcinomas tend to recur after hormonal therapy as carcinomas
with focal NED [reviewed in Ref. (3)]. It is worth noting that a
correlation between NED and poor prognosis would be encoun-
tered in both scenarios (NED as merely associated with, vs. NED
as causatively related to, poor prognosis). This correlation is likely
to have a strong impact on a grand scale, because PCa is the most
common cancer and the second-leading cause of cancer death in
American men (108). Thus, even though patients diagnosed with
advanced PCa represent only a small fraction of the total number
of PCa cases, they still represent a high absolute number. Con-
sequently, the ADT-induced NED, which is encountered in these
patients, also is expected to occur in a high absolute number of
patients.
It is difficult to get an accurate picture of the association
between NED and prognosis, mainly because of the lack of large,
conclusive studies. Instead, many studies report that NED corre-
lates with poor prognosis, and still other studies fail to report such
association. The main reason is the methodological heterogeneity
in common practice to detect and quantify NED, to collect biologi-
cal material, and to devise patient inclusion criteria [for a snapshot
see Ref. (40)]. This heterogeneity is threefold.
First, NE cells produce a vast array of neuropeptides that are
used somewhat stochastically in immunostaining procedures to
identify NED. However, the freedom to choose among various
markers relies on the assumption that NED markers are equiv-
alent to one another, i.e., they are present in the tissue in equal
or proportional quantities. But is this assumption true? The most
recent explicit methodological directive implies that any of the
three common markers (CgA, NSE, or synaptophysin) is sufficient
to document NED (8) (Figure 5). In patients with either localized
or advanced (stage D2) PCa, strong CgA staining of primary tumor
correlates with poorer cause-specific survival (109, 110) and over-
all survival (90) and provides superior information as compared to
currently used pathologic prognostic factors (109). Similarly, CgA
abundance in lymph node deposit also correlates with poorer over-
all survival (90). By contrast, NSE staining of primary tumor does
not correlate with survival (110). In fact, as stated above, NSE was
equally expressed in tumoral, peritumoral, and benign prostatic
hyperplasia (BPH) tissue (10), which suggests that it lacks clini-
cal significance. Thus, although not systematically demonstrated,
CgA is the most clinically relevant NED marker (91) and has been
used in most studies addressing the clinical implications of NED.
Second, tumor samples can be obtained either through a sur-
gical intervention or a core needle biopsy. However, the freedom
to choose between these two procedures relies on the assump-
tion that they are equivalent procedures. But are they? At a first
glance, while surgery ensures pathological sampling access to the
whole tumor, biopsy is like looking through the keyhole. It is
thus unclear if NED seen in the biopsy accurately mirrors the
NED of the whole tumor. In tumor biopsies from patients with
advanced PCa (stage D2), strong CgA immunostaining was corre-
lated with higher 2-year recurrence rates and much shorter time to
recurrence (111). Moreover, in biopsies from an unselected popu-
lation of patients with PCa, biopsy CgA immunostaining positivity
correlated with shorter survival (112). Similarly, in biopsies of a
selected population of patients with ADT-resistant PCa, NED cor-
related with decreased cancer-specific survival (113). Additionally,
in core needle biopsies from PCa patients with Gleason score
8–10 who received primary radiotherapy, CgA immunostaining
>1% correlated with less favorable biochemical control, clinical
failure, distant metastases (sixfold), and cancer-specific survival
FIGURE 5 | Prostate cancer immunostaining for neuroendocrine
markers. In surgical or core needle biopsy samples, NED can be detected
by immunostaining against specific markers, most notably peptides, which
are present inside the NE secretory vesicles (see text for details). A
frequently used NED marker is the enzyme NSE, seen here as brown
cytoplasmic granules. Immunoperoxidase stain. Courtesy and with
permission of Dharam M. Ramnani, MD; WebPathology.com.
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(almost fivefold) rates as compared to CgA immunostaining<1%
or negative CgA immunostaining, respectively (92). Other authors,
however, after assessing biopsies from patients with ADT-resistant
PCa, reported no significant correlation between CgA serum lev-
els and biopsy CgA immunostaining intensity (12). Because CgA
serum levels correlate with CgA immunostaining in the primary
tumor (see below), biopsy tissues may provide a distorted, inac-
curate image of NED. To avoid this gray zone of uncertainty, a
best approach might be to use biopsy CgA immunostaining in
tandem with CgA serum levels to increase overall accuracy (114).
Although, in most cases, biopsy appears to provide a fair image of
the extent of NED in the primary tumor, it should be remembered
that surgical samples provide the most reliable snapshots of NED.
Third, a majority of the neuropeptides can not only be viewed
immunohistochemically but also can be measured in serum. How-
ever, the freedom to choose between these two methods relies on
two assumptions: (i) NED markers produced by NED cells are
released into the bloodstream, and (ii) there is a linear relation-
ship between NED in the tissue and NED markers in the blood.
But are these two assumptions true? While obtained more easily
and less invasively, serum levels provide an indirect (and perhaps
distorted) measure of the NED presence and extent. In addition,
blood levels of several NED markers can increase in non-NED
settings which thereby act as confounders (e.g., chronic use of pro-
ton pump inhibitors increases CgA levels nearly eightfold) (115).
However, CgA serum levels do correlate with CgA staining of pri-
mary tumor, and they also correlate with CgA staining of biopsy
samples (9, 110, 114), which suggests that serum CgA accurately
mirrors the extent of NED in PCa. By contrast, no correlations
exist between immunohistochemical staining for chromogranin
B, NSE, and pancreastatin, respectively, and the corresponding
serum levels of those markers (9, 110). Thus, CgA is the most reli-
able serum marker of NED (9). CgA serum levels are higher in PCa
as compared to BPH, and they are higher in BPH as compared to
healthy controls (116). In patients with ADT-resistant PCa, high
serum levels of CgA correlate with reduced overall survival (12).
In patients with ADT-resistant PCa who had not received any
prior chemotherapy, CgA serum levels increased rapidly over time
(twofold in 9 months), correlate negatively with survival, and are
an independent predictor of survival (117, 118). However, this
might only apply for a subset of patients. Two groups showed that,
in patients with advanced PCa, elevated serum CgA only corre-
lates with poor prognosis when serum PSA is below or equal to
the median value, but fails to correlate when serum PSA is above
the median value (117, 119). The relationship between serum
NSE levels and prognosis is less clear-cut, but positive correla-
tions have been reported. NSE serum levels are higher in PCa as
compared to BPH and they are higher in BPH than in healthy con-
trols (116). In patients with advanced PCa, elevated pre-treatment
serum levels of NSE correlate with short survival (120). However,
in patients with advanced PCa, pre-treatment serum levels of NSE
do not correlate with those of CgA, which correlate with NED
and prognosis. Moreover, following palliative radiotherapy, serum
levels of NSE drop while serum levels of CgA and PSA increase.
This suggests that CgA- and NSE-secreting NE cells differ from
each other in terms of radiosensitivity (120). The authors rely on
this finding to suggest that NSE, rather than providing prognostic
information, might actually help monitor the response to palliative
radiotherapy (120).
Associations between NED and other tumor features also are
linked to prognosis. Quek’s group found that NED in the primary
tumor correlates with clinical recurrence (90). Others reported
that NED correlates with high Gleason score (88, 89, 114, 116,
121), tumor stage (89, 112, 114, 121), and the presence of metas-
tases (89). Pattern of NE cell growth also is important. Tumors
with high Gleason score (7 to 10) tend to show clusters of NE
cells, while most tumors with low Gleason score display solitary
NE cells, and presence of clusters appears to impart a poorer
prognosis (47). NED also correlates with serum PSA levels, but
conflicting evidence exists regarding the directness of the cor-
relations (114, 121). Similar observations, with less specific NE
markers, were made by Ishida’s group. In tumor samples from
patients who had not received preoperative therapy, the presence
of calcitonin correlated with high Gleason score, suggesting an
association with cancer aggressiveness or invasion (86). Further-
more, in PCa patients, serum levels of CgA and NSE correlated
with tumor stage, with a slightly higher resolution for CgA (116).
Not all the studies have found associations between NED and
clinical, biochemical, or pathological features of PCa. Various
authors failed to report any correlation between NED and prog-
nosis, failure after radical prostatectomy, clinical stage, Gleason
score, tumor stage, or lymph node metastasis (42, 88, 122). Oth-
ers reported no correlation between NED and proliferation index
or disease progression (42), or between NED and PSA levels or
PSA progression (89, 112). Among the most widely used NED
markers, NSE serum levels failed to correlate with Gleason score
(116). Some of these studies, however, did not properly explore
the correlations between NED and survival or between NED and
more specific subsets of patients (e.g., those receiving ADT or dis-
playing CR) (42, 122). This is precisely why these null results are
important. That is, if corroborated with the correlations described
before, they suggest that NED might rather predict a poor response
to ADT than a globally poor prognosis (42, 112). Indeed, in PCa
biopsies from patients with newly diagnosed PCa who subse-
quently received ADT, high CgA immunostaining correlated with
faster progression to CR and lower overall survival; moreover, in
these patients, CgA serum levels almost doubled after 2 years of
ADT (114). This increase in CgA serum levels during ADT might
reflect the development of increased tumor aggressiveness and CR
(114). Furthermore, although biopsy CgA immunostaining does
not correlate with shorter time to PSA progression in patients
not treated by ADT, it does correlate in those receiving ADT (112).
The correlation between NED and prognosis might therefore need
to be stratified further across patient subsets, most notably those
receiving ADT. In addition, a methodological systematization with
respect to selecting a more restrictive panel of NED markers to be
used [see, e.g., Ref. (12)] and specifying the methods for collecting
the NED markers thus is paramount.
The conclusions from these data are: (i) universal NED (SCCP)
correlates with poor response to therapy and particularly dim
prognosis. Moreover, universal NED includes a large family of
tumors that display similar histological, clinical, and prognostic
features irrespective of the organ site of origin. This suggests that
NED, or at least the extreme end of the NED spectrum, might
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actually be a rather unique and homogenous disease entity despite
its various organ starting points. An in-depth, all-organ-site his-
tological, genetic, phenotypical, and clinical comparative analysis
of focal NED is warranted; (ii) focal NED correlates with tumor
aggressiveness and poor prognosis, particularly in patients receiv-
ing ADT; (iii) CgA is the most reliable immunohistochemical NED
marker; (iv) core-needle biopsies provide an accurate snapshot of
NED. However, until larger studies are done, surgery remains the
gold standard for visualizing NED; (v) serum CgA is the most reli-
able serum NED marker; and (vi) large studies are needed to help
standardize the methodology for detecting and quantifying NED.
INTERLEUKIN-6 AND NEUROENDOCRINE DIFFERENTIATION
Interleukin (IL)-6 plays a key role in ADT-induced NED (63–70,
75). In PCa tissue, IL-6 is found in higher concentrations (albeit
more variable in terms of range) than in non-cancerous prostate
tissue (69). IL-6 is secreted by several PCa cell lines (PC3, DU145,
and TSU), as well as by normal prostatic epithelial cells. By con-
trast, LNCaP PCa cell line does not secrete IL-6 (66, 69). However,
IL-6 receptor is present in all the aforementioned PCa cell lines,
including LNCaP (66). Similarly to IL-6, concentrations of IL-
6 receptor are higher in PCa, but more heterogeneous in terms
of range, as compared to non-cancerous prostate tissue, and its
level of expression across PCa samples correlates with increased
proliferation (69).
Interleukin-6 induces NED in PCa cell lines, most notably
LNCaP, C4-2, and C4-2B (64, 66, 68, 75, 123). The LNCaP cell line
provides the model of choice for studying transition of PCa from
androgen sensitivity to CR. Because NED and CR in PCa go hand-
in-hand (see above), it is not surprising that IL-6 also induces CR.
Hobisch’s group was among the first to show that, in principle, IL-6
can activate the AR in an androgen-independent, dose-dependent
fashion. The IL-6-activated AR, in turn, activates its target genes
at 67% of the level reached in the androgen-activated AR scenario
(63). Interestingly enough, IL-6 and androgens have synergistic
effects when co-administered in low concentrations, but this addi-
tive pattern disappears as IL-6 concentration is increased. The syn-
ergistic AR activation by IL-6 and androgens is almost completely
inhibited by bicalutamide, an AR blocker (63). In LNCaP cells,
IL-6 also activates AR in an androgen-independent fashion (65),
increasing AR-regulated PSA gene expression and consequently
increasing PSA mRNA and secreted protein levels (63, 70). Co-
administration of IL-6 and androgen has a synergistic effect that
is blocked by bicalutamide (63, 70). In C4-2 and C4-2B cell lines,
IL-6 is a key mediator of bone marrow stroma-induced NED and
autophagy (75, 123). Because both NED and autophagy are highly
protective for PCa cells, IL-6 might facilitate bone metastasis.
Both NED and CR influence tumor growth. However, the effect
of IL-6 on tumor growth remains debatable. In LNCaP cells, sev-
eral groups showed that IL-6 induces growth (66, 69, 70) while
decreasing cell death and proportion of S-phase cells (69). By
contrast, others found that IL-6 inhibits LNCaP cell growth via
the IL-6 receptor subunit gp130 (64, 67) and decreases prolifer-
ation induced by androgens (63). IL-6 inhibits tumor growth by
blocking the cell cycle in the G1 phase (64). Cell cycle G1 arrest
is associated with an increase in p27Kip1 levels and a decrease in
CDK2, CDK4, and CDK6 levels (64).
SIGNALING PATHWAYS USED BY INTERLEUKIN-6 TO
INDUCE NEUROENDOCRINE DIFFERENTIATION
The signaling pathways that IL-6 relies on to induce NED and
related processes are only partially known and their operation
principles are yet to be revealed. It is known that the JAK/STAT3
system, which is a downstream effector of IL-6, is particularly
important. Ni and his group found that STAT3 (but not STAT1) is
constitutively active in human PCa cell lines (LNCaP, PC3, DU145,
TSU) as well as in various Dunning rat PCa sublines (124). Gao’s
group reported that, in LNCaP and PC3 cell lines, as well as in
PCa samples, STAT3 protein levels are increased twofold over nor-
mal prostate tissue (125). In both human and rat PCa cell lines,
STAT3 binding activity is correlated with tumor aggressiveness
(124). However, other authors report that PC3 cells do not express
STAT3 (67).
Giri’s group reported that IL-6 induces phosphorylation and
nuclear translocation of STAT3 in both prostatic normal epithe-
lial and LNCaP cells (69). Ueda’s group found that, in LNCaP
cells, IL-6 activates the whole JAK/STAT3 system with consequent
STAT3 phosphorylation at both sites of regulation (Tyr705 and
Ser727, respectively) (70). In LNCaP cells, IL-6-induced activation
of STAT3 triggers NED (66, 68). Furthermore, in PC3 cells, which
normally do not express STAT3 (67), overexpression of STAT3
leads to NED (67). Similarly, in C4-2 and C4-2B cells, IL-6 induces
NED via activation of STAT3 (75).
In LNCaP cells, JAK/STAT3 signaling also is required for IL-
6-induced, AR-mediated gene activation (65). Activated STAT3
associates with AR N-terminal domain (70) in an androgen-
independent, IL-6 dependent fashion (65). To this end, phos-
phorylation, dimerization, and DNA binding of STAT3 (but not
STAT1) are crucial. Any one of the AR N-terminal domain regions
234–390 and 391–588 (which STAT3 binds to) can drive the
process. By contrast, the 1–233 regions, which do not bind STAT3,
are not essential (70). Ueda’s group found that, although JAK plays
an important role in general, it is not essential in this specific
context (70).
The roles of JAK/STAT3 in NED- and CR-related processes,
most notably tumor growth, are still debated. In TSU cells, phos-
phorylation of STAT3 (via JAK) is required for tumor growth.
Thus, overexpression of phosphorylation- and activity-defective
STAT3F mutant reduces TSU growth in vitro, while decreasing
tumorigenicity of TSU cells injected in vivo (124). However, Spi-
otto and Chung reported that TSU line is refractory to STAT3
signaling (or at least to STAT3 signaling induced by IL-6) because
of decreased STAT3 tyrosine phosphorylation (67). In LNCaP
cells, STAT3 is not essential for cell growth, because wild type and
mutant STAT3F cells exhibit similar growth (67). In LNCaP cells,
rather than influencing default growth, STAT3 might modulate
responses to external signals. Thus, in LNCaP cells expressing wild
type STAT3, IL-6 inhibits growth, whereas in LNCaP cells express-
ing STAT3F mutant, IL-6 enhances growth (67). In PC3 cells,
transfected STAT3 inhibits growth (68), while STAT3 knockdown
inhibits growth {accompanied by a decrease in c-myc mRNA levels
[although see Ref. (67)]}, increases apoptosis (accompanied by a
decrease in Bcl-2 protein levels), and induces cell cycle G1 arrest
(accompanied by a decrease in cyclin D1 protein levels) (125). In
PC3 cells injected in vivo, STAT3 knockdown markedly decreases
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tumorigenic potential and induces intense tumor apoptosis (125).
Structurally, the Src homology 2 domain of STAT3 is key in medi-
ating all these effects (125). The DU145 cell line exhibits reduced
STAT3 DNA binding, which makes DU145 cells unresponsive to
STAT3-mediated IL-6 signaling (67).
It is likely, but yet to be confirmed, that IL-6 participates in
more than one signaling pathway to induce these effects. In C4-
2 and C4-2B cells, STAT3 activation is required for IL-6-induced
NED, but not for IL-6-induced autophagy, which suggests that IL-6
induces these two effects through distinct signaling pathways (75).
Besides JAK/STAT3, the other canonical signaling pathways in IL-6
signaling are MAPK and PI3K-Akt. In LNCaP cells, MAPK path-
way is required for IL-6-induced (but not for androgen-induced)
activation of AR N-terminal domain (70) and consequent expres-
sion of AR target genes (63). However, Chen’s group failed to
show any such effect in LNCaP cells (65). In IL-6-treated LNCaP
cells, the effects of MAPK pathway, if any, do not proceed via
JAK/STAT3 phosphorylation; however, some cross-talk is possi-
ble as IL-6 induces JAK to phosphorylate MAPK (70). In DU145
cells, MAPK pathway is necessary for IL-6-induced, but not for
androgen-induced, activation of AR and expression of the lat-
ter’s target genes (63). The PI3K pathway plays a minor role,
if any, in IL-6-induced activation of AR N-terminal domain in
LNCaP cells (70). Interestingly enough, cAMP and protein kinase
A (PKA), as well as protein kinase C, may be involved in IL-6 sig-
naling. In LNCaP cells, inhibition of PKA decreases IL-6-induced,
AR-mediated gene expression, while not influencing androgen
signaling via AR (63). In DU145 cells, PKA is required for AR
signaling induced by either IL-6 or androgens. In DU145, pro-
tein kinase C influences AR signaling induced by IL-6 (but not by
androgens) (63).
CORRELATIONS BETWEEN PROSTATE CANCER AND NEURAL
STRUCTURES
The significance of NED in PCa is emphasized by the finding
that PCa cells benefit from close contact with neural structures. A
remarkable attempt to systematize this emerging field was made
by Zänker and Entschladen (126). In tissue samples, PCa cells
involved in perineural invasion display increased proliferation and
decreased apoptosis as compared to PCa cells located away from
the nerves (127). Similarly, in an in vitro model, first described
in Ref. (128), DU145 cells involved in perineural invasion-like
actions exhibited increased proliferation and decreased apopto-
sis, accompanied by an upregulation of several genes and corre-
sponding proteins, three of which (NF-κB, PIM-2, and DAD-1)
play anti-apoptotic roles (127). Pharmacologic inhibition of NF-
κB reversed most of these effects, as it increases apoptosis and
down-regulates NF-κB, PIM-2, and DAD-1 proteins (127). Fur-
thermore, in tissue samples, NF-κB is expressed in higher levels
in PCa cells involved in perineural invasion than in correspond-
ing PCa cells remote from the nerves (127). Collectively, these
results suggest that NF-κB plays a key role in PCa cells prolif-
eration and survival driven by perineural invasion. Interestingly,
high NF-κB nuclear expression in PCa cells exhibiting perineural
invasion correlates with recurrence-free survival (127). In addi-
tion, PCa cells undergoing perineural invasion upregulate TGFβ1
secretion, which stimulates the perineurium of invaded nerves to
secrete caveolin-1. The latter, in turn, inhibits apoptosis in PCa
cells (129).
While at least some of the findings above might be the
accounted for by the neural stroma, lines of evidence implicate
neurons themselves. In mice, prostatic adrenergic sympathetic
nerve fibers contribute to the initial stages of PCa development
via stromal β2- and β3-adrenergic receptors, whereas choliner-
gic parasympathetic nerve fibers play a key role at later stages
of tumor invasion, migration, and metastasis through stromal
M1 muscarinic receptors (130). Interestingly, rather than being
skewed in favor of PCa cells, the benefits of perineural invasion
might be shared. It has been reported that patients with PCa
and preneoplastic lesions have increased global nerve density in
the prostate as compared to healthy individuals. Nerve density is
higher in tumor foci as compared to non-tumoral regions and
healthy prostates, respectively (131), and correlates with increased
proliferation of PCa cells and activation of cell survival path-
ways (including PTEN/Akt-1 and downstream effectors FKHR
and GSK, as well as NF-κB and downstream effectors PIM-2 and c-
Myc) (132). Furthermore, axonogenesis correlated with aggressive
disease and biochemical recurrence (131). In an in vitro scenario
DU145 cells involved in perineural invasion-like processes upreg-
ulated semaphorin 4F gene, which increased neurogenesis (131).
Thus, a symbiotic contract might occur between PCa cells and
adjacent neural structures (128). One interesting aspect is that
not only epithelial but also NE tumor cells can undergo per-
ineural invasion (13). Finally, the Ayala group in collaboration
with our group has evidence that PCa cells can adopt a true neural-
mimicking phenotype, demonstrated by identification of a subset
of “high in brain” expressed genes that also are high in PCa metas-
tases in patients with ADT, and which are proposed to be part
of a treatment-resistant phenotype (Farach et al., in preparation).
Although they need to be taken cum grano salis, these findings
beg the question of how a malignant tissue benefits from cre-
ating neural-like cells. Because the nervous system is the master
device that deals with stress, and ADT is itself a stressful situation,
a truly neural differentiation within PCa tissue would seem less
far-fetched. But are there any other lines of evidence to support
such claims?
The mutual interplay between PCa and neural structures, and
the potential advantage of a neural-mimicking PCa phenotype,
is supported by the consistent finding that patients with spinal
cord injury (SCI) have lower risk of developing PCa than those
without SCI (133–136). These findings are consistent with the
more general observation that patients with severe SCI have a
smaller prostate (133, 137). Several explanations for this phe-
nomenon have been proposed [reviewed in Ref. (135)], mostly
related to the disruption of prostatic regulatory neurohormonal
axes following the spinal lesion (133, 134). This would account
for the observation that risk for PCa is lower only for higher
level SCI (above vs. below T6 has been the only cutoff level
investigated so far) (135), as prostatic innervation involves lower
spinal segments (21). Furthermore, in patients undergoing radi-
cal prostatectomy for PCa, general anesthesia (GA) plus neuraxial
(spinal or epidural) anesthesia/analgesia (NAA) is associated with
lower risk of systemic progression, lower risk of biochemical
recurrence, and lower overall mortality as compared to GA plus
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postoperative opioid analgesia (138, 139). We suggest that this
would make sense particularly if one viewed NAA as a tempo-
rary, chemical SCI due to the sodium channel blocking action of
the agents used, which temporarily interrupts the neural path-
ways. Inhibition of tumoral voltage-gated sodium channels by
non-anesthetic agents inhibits migration, invasion, and metasta-
sis; it has thus been proposed that local anesthetics, due to their
main action as voltage-gated sodium channel blockers, might have
similar anticancer effects [reviewed in Ref. (140)]. Moreover, cells
derived from tumors with universal NED, such as SCLC, gen-
erate action potentials relying on inward sodium and outward
potassium currents (141, 142). Likewise, normal NE cells in the
lung are excitable, rely on voltage-activated potassium, calcium,
and sodium currents, and exhibit spontaneous firing modulated
by hypoxia [reviewed in Ref. (4)]. In the androgen-independent
PCa cell line PC3, growth is inhibited by voltage-gated sodium
channel blockers, and the potency of the growth-inhibitory effect
is roughly proportional to the potency of the sodium channel-
inhibitory effect (143), suggesting that the latter accounts for the
growth inhibition.
One important functional difference between NAA and a real
SCI is that the former, in dosages commonly used in the clinic,
preferentially targets the sensory nerve fibers while leaving the
less susceptible motor fibers relatively unblocked (144). However,
it is the sensory, and not the motor innervation of the prostate,
which is responsible for neural regulation and support of prostate
growth and development (21). It is thus tempting to construct
a unified hypothesis, in which the PCa/nerve symbiosis accounts
for the reduced risk for PCa in patients with damaged prosta-
tic innervation following SCI, which further explains the reduced
risk for PCa recurrence in PCa patients with temporarily dam-
aged prostatic innervation following NAA (Figure 6). Attempts
to target PCa with neurotropic agents that block the generation
or transmission of action potentials are thus legitimate. Botu-
linum toxin has been shown to inhibit the growth of LNCaP cells
in vitro and in vivo (145), and an ongoing clinical trial is investigat-
ing the effects of botulinum toxin on PCa (see NCT01520441 on
www.clinicaltrials.gov). Before pursuing this lead, however, one
should first determine if the observed effects of NAA might be
better accounted for by non-neurotropic factors.
It is widely assumed that most general (as opposed to neu-
raxial) anesthetics are immunosuppressive, mainly by decreasing
natural killer (NK) cell activity, and promote cancer metastasis
[Ref. (146); also reviewed in Ref. (140)]. NAA might help avoid
this immunosuppression by reducing the use of GA [reviewed in
Ref. (140)]. However, several studies found that patients receiving
both GA and NAA had better outcomes in terms of PCa biochem-
ical recurrence (138), local recurrence (147), systemic progression
(metastasis) (139, 147), and/or mortality (139), or in terms of col-
orectal cancer mortality (148) than patients receiving GA alone.
Because GA was given to both study arms, it follows that in all these
cases NAA did not help avoid the use of GA. If the only anticancer
effect of NAA was to help avoid GA, then no significant differ-
ences in terms of immunosuppression should have been present
between the arms. Still, significant differences in outcome were
present. Thus, it follows that NAA might act through additional
undiscovered mechanisms.
FIGURE 6 | Neuraxial anesthesia/analgesia as a “temporary spinal
cord injury.” (A) At the micro level, neurons (left) and prostate cancer cells
(right) engage in a symbiotic, mutually growth-supportive relationship
(green arrows). One NE cancer cell, displaying secretory granules, also is
depicted between the non-NE cells. (B) (Left) At the macro level, sensory
prostatic neurons (blue), but not motor prostatic neurons (magenta) support
growth of the prostate gland (green arrow). (Middle) At the macro level, SCI
(oblique black bar) disrupts prostatic innervation (dashed sensory and motor
prostatic neurons), which consequently impairs growth and reduces (red
saltire) the risk for developing PCa (light purple oval). (Right) During PCa
surgery, NAA also disrupts prostatic sensory innervation (dashed sensory
prostatic neurons) by pharmacologic blockade (oblique red bar-headed line),
which reduces risk (red saltire) for recurring PCa (dotted light purple oval
line). It is thus reasonable to infer that NAA induces a “temporary SCI” that
inhibits PCa similarly to SCI-induced sensory neuronal damage (see text for
details). N, neurons; PCa, prostate cancer; SC, spinal cord; P, prostate; SCI,
spinal cord injury; NAA, neuraxial anesthesia/analgesia.
Opioid agents, which are routinely used for surgical analge-
sia, are immunosuppressive [reviewed in Ref. (140)]. Another
proposed mechanism by which NAA decreases perioperative
immunosuppression is through reducing the need for systemic
opioids [reviewed in Ref. (140)]. Sprung’s group performed two
significant retrospective studies that showed that opioids can be
important confounders. In patients undergoing radical prostatec-
tomy for PCa, GA plus NAA lowered risk of systemic progression
and overall mortality as compared to GA plus postoperative opi-
oid analgesia (139). Interestingly, no significant differences were
found when NAA scheme included fentanyl (149), which is rapidly
absorbed into the systemic circulation due to its high liposol-
ubility [reviewed in Ref. (149)]. The beneficial effects of NAA,
including the decreased need for systemic opioids, might have
been neutralized by the immunosuppressive effects of fentanyl
escape into the bloodstream (149). The same should in princi-
ple apply to the other lipophilic opioids (e.g., sufentanil), which
might explain why studies in which the NAA patients received
intraneuraxial lipophilic opioids (150–153) found no significant
differences between the two anesthetic techniques (149). The other
studies reporting non-significant or equivocal differences did not
mention the pharmacologic agents used (147, 154–156).
It is expected that NAA works through both mechanisms
described above, i.e., helping avoid both GA and systemic opioids
[reviewed in Ref. (140)]. However, a careful inspection reveals
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that both mechanisms rely on the passive avoidance of an extrinsic
pharmacological effect of some other agent, rather than the active
promotion of an intrinsic pharmacological effect of their own. In
other words, NAA is devoid of antitumor effect per se, which has
actually been proposed (149). This being the case, adjusting for
the corresponding confounders, i.e., presence of GA in both arms
under study and intraneuraxial injection of lipophilic opioids in
patients receiving NAA, should render uniform results across var-
ious cancer types. However, the results indicate that this is not
the case. In patients undergoing surgery for non-metastatic rectal,
as opposed to colon cancer, GA plus NAA followed by postoper-
ative NAA were associated with reduced mortality as compared
to GA alone followed by postoperative opioid analgesia (148).
The fact that the NAA arm had better outcomes in rectal can-
cer patients is unexplainable, as no significant differences were
found between the two cancer type groups (rectal vs. colon) with
respect to the inclusion of opioids or the inclusion of lipophilic
opioids in the NAA regimen, and GA was used in both therapeutic
arms for both cancer type groups (148). Therefore, any confounder
determined by the rapid absorption of neuraxially administered
fentanyl or sufentanil into the systemic circulation, as well as any
confounder related to GA use in both arms, should have mani-
fested itself uniformly across the two cancer types. Besides that,
opioids do not have significant immunosuppressive effects in col-
orectal cancer. Patients with colorectal cancer display suppression
of NK cell activity, which has important prognostic significance
and is reversed following tumor resection [reviewed in Ref. (157)].
However, opioids given in analgesic concentrations do not induce
NK cell-mediated immunity in treated patients (158). In fact,
some opioids, including fentanyl, might increase NK cell activ-
ity [reviewed in Ref. (158)] or even have antitumor effects on
colon cancer in vivo [reviewed in Ref. (159)]. Given these find-
ings, we suggest that a plausible explanation for the observed
discrepancies between rectal and colon cancer patients would be
that NAA has a pharmacological antitumor effect per se. In other
words, this is not a merely passive antitumor effect due to avoiding
immunosuppressive factors, but rather an active antitumor effect,
either due to inhibiting immunosuppressive factors and/or to pro-
moting or inhibiting non-immunological factors. Such an intrinsic
pharmacologic action could explain why NAA yields better out-
comes in some, rather than all, cancer types, including prostate
(138, 139), breast (160), hepatocellular (161), rectal (148), ovarian
(162), and melanoma (163); also see Ref. (164) and the references
therein.
Obviously, this simple arithmetic cannot cover all the details.
It is difficult to speculate upon the nature of the active anti-
immunosuppressive effect of NAA, if any, mostly because it
has become increasingly clear that cancer-associated immune
response and immunosuppression are tumor type-specific and
correlate with disease staging, therapy, and prognosis [see Ref.(157,
165, 166) and the references therein]. In particular, this holds for
PCa (167). However, it has been suggested that NAA decreases
perioperative immunosuppression through blocking sympathetic
activation and decreasing plasma levels of catecholamines and
cortisol [reviewed in Ref. (140)]. These are genuine neurotropic
effects, which makes the neurotropic-based antitumor effect of
NAA plausible.
In the same vein, it remains to be seen if NAA has active non-
immunologic, neurotropic anti-PCa cell growth effects. A recent
meta-analysis found no significant differences between the effect
of NAA and GA, respectively, on postoperative function of NK T
lymphocytes (168). Since NK T lymphocytes are crucial for anti-
cancer immunity [reviewed in Ref. (168)], it might be that NAA
does not differ from GA in terms of immunosuppression. In this
case, the beneficial effects of NAA on cancer outcomes as com-
pared to GA might be better explained by active non-immunologic
effects of the former rather than by active immunologic effects.
Because the antitumor neurotropic effect, be it immunologic or
non-immunologic, seems the most plausible scenario, we argue
that it is legitimate to start by seeking non-immunologic effects of
NAA on PCa that are also neurotropic in nature, most notably a
disruption of the PCa/neural symbiosis.
CORRELATIONS BETWEEN PROSTATE CANCER AND NEURAL
FUNCTIONS
In addition to these associations between PCa and peripheral
neural structures, a growing body of evidence indicates an exist-
ing association between PCa and central neural functions. This,
too, might shed light upon the significance of processes such
as NED. Following almost a century of observations, systematic
nationwide studies conducted during the last three decades have
revealed an intriguing association between schizophrenia and a
reduced risk for cancer as compared to the general population
(169–175), although two other nations reported no difference or
even an increased risk (176, 177). The reduced risk is more perva-
sive in males (169, 170, 172, 174, 175), and the risk reduction most
consistently reported is for PCa [Ref.(169, 171–175); a similar, yet
not significant trend was also reported in Ref. (178)]. The mecha-
nisms responsible for these findings are incompletely understood,
but use of antipsychotic drugs,which are used in several psychiatric
disorders, including schizophrenia, correlates with reduced risk of
developing cancer (179, 180), most notably PCa (179). A protective
genetic trait cannot be ruled out, though, because some instances
of cancer risk reduction in schizophrenia had first been mentioned
in 1909 [reviewed in Ref. (177)], that is, some 45 years before the
discovery of antipsychotics (181). A meta-analysis reported large
sets of genes and pathways that are dysregulated in opposite direc-
tions between three CNS disorders (schizophrenia, Parkinson’s,
and Alzheimer’s disease) and three cancers (PCa, lung, and col-
orectal cancer), either by being upregulated in one or more of
the three CNS disorders and downregulated in one or more of
the three cancers, or vice versa (182). On the other hand, the up-
or downregulation of at least some of these genes and pathways
might be medication-related rather than owed to the disease itself.
This leaves open the possibility that some of the drugs used in
CNS disorders might downregulate certain oncogenes, or upreg-
ulate certain tumor suppressor genes, thus conferring anticancer
protection (182). Furthermore, parents with schizophrenic off-
spring have the same risk for developing cancer as parents with no
schizophrenic offspring [Ref. (183), although see Ref. (174, 176),
but in these studies the controls were general population rather
than parents with healthy offspring]. This suggests that it is a
non-shared, environmental, rather than a shared, inherited factor,
which accounts for most anticancer protection in schizophrenics,
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which further supports the antipsychotic medication hypothesis.
Among the antipsychotics currently used, phenothiazine com-
pounds are best documented to associate with decreased risk for
cancer, most notably PCa (179).
Experimental findings lend further support to these clinical
findings. In vitro, trifluoperazine, a phenothiazine antipsychotic
agent, decreases proliferation, induces depletion of cancer stem
cells (CSCs), and overcomes gefitinib resistance in non-small
cell lung cancer (NSCLC) cell lines (184). Similarly, thioridazine,
another phenothiazine antipsychotic agent, selectively induces dif-
ferentiation (i.e., loss of pluripotency) of human CSCs both in vitro
and in vivo (namely, acute myeloid leukemia stem cells) while
sparing normal stem cells, and allows for 100-fold dosage reduc-
tion of the antileukemic drug cytarabine when co-administered
with it (185). Moreover, the mechanism of action involves mainly
D2 dopamine receptors, which also account for the antipsychotic
effects of the agent (181, 186). Further extending the screen-
ing pool identified two additional phenothiazine agents (namely,
prochlorperazine and fluphenazine) as having similar effects on
CSCs in vitro. Although the pharmacologic effects of these addi-
tional two agents were weaker and less selective as compared
to thioridazine (185), the data collectively raise the interest-
ing possibility that the effect on CSCs might be a class effect
(187).
INTERLEUKIN-6 IS A COMMON DENOMINATOR IN THE
PATHOGENESIS OF NEUROENDOCRINE DIFFERENTIATION
AND SCHIZOPHRENIA
Apart from playing a central role in ADT-induced NED, IL-6 has
recently come to attention as a key player in the pathogenesis of
schizophrenia. The evidence for this is fourfold.
First, patients with schizophrenia (especially those previously
untreated or not receiving medication for prolonged periods of
time) have high plasma levels of IL-6 compared to healthy con-
trols (188–191), and the increased levels correlate with acute phase
(192). However, antipsychotic treatment decreases plasma levels
of IL-6 and soluble IL-6 receptor (188, 189). Plasma levels of IL-6
also are increased in elderly schizophrenics with long-term dis-
ease and persisting symptoms despite long-term therapy, which
could reflect resistance to therapy and thus explain the apparent
paradox (193).
Second, in middle-aged adults, plasma levels of IL-6 correlate
inversely with the volume of hippocampal gray matter (194). The
hippocampus is an important brain region linked to the anatomic
basis of schizophrenia [reviewed in Ref. (195)], and hippocampal
volume is decreased in schizophrenic patients (191).
Third, IL-6 gene polymorphism is associated with schizo-
phrenia [Ref. (190), although see Ref. (196)] and reduced hip-
pocampal volume occurs in antipsychotic-naïve schizophrenic
patients (191).
Fourth, IL-6 is a key player in established pathogenic models
of schizophrenia, including the “ketamine model” (197). Namely,
IL-6 acts as a key downstream effector of the NMDA recep-
tor antagonist ketamine that activates NADPH oxidase in the
brain, leading to increased superoxide production and consequent
dysfunction of parvalbumin-expressing inhibitory interneurons
(197). The dysfunction of these GABA-ergic interneurons, in turn,
has been linked to the pathogenesis of schizophrenia [reviewed in
Ref. (197)].
CONCLUDING REMARKS: SEEKING NEURAL
DIFFERENTIATION IN PROSTATE CANCER
It is commonly accepted that PCa NED is enrichment of a cell
subset that secretes various neuropeptides leading to CR of PCa
[see, e.g., Ref. (49)]. It is thus not surprising that PCa NED most
frequently appears following ADT and therefore acts as an“escape”
mechanism whereby advanced PCa can evade current therapeu-
tic strategies. A crucial molecular mediator is IL-6, which acts as
a signaling bridge linking ADT, via STAT3 and activation of AR
target genes in the absence of androgens, to the ensuing NED
and CR.
Prostate cancer also displays profound correlations with neural
structures: (i) at the sub-micro level, PCa cells express many genes
expressed in neurons and other CNS cells; (ii) at the micro level,
PCa and neurons engage in a symbiotic-like relationship; (iii) at
the macro level, SCI reduces risk for PCa [which further explains
(ii)]; (iv) at the macro level, NAA, but not GA, reduces risk for
PCa recurrence by acting as a “temporary SCI” through blocking
the action potentials of sensory neurons. The NED cancers also
exhibit action potentials [which further supports (ii) and (iii)].
Prostate cancer also is associated intimately with neural func-
tions: (iv) schizophrenia decreases risk of cancer, most notably
PCa; (v) antipsychotics explain this risk reduction; (vi) at the micro
level, antipsychotics exhibit strong anticancer activity, including
strong effects on CSCs; (vii) IL-6, the prima donna of ADT-
induced NED, is a key player in the pathogenesis of schizophrenia.
Its high levels encountered in these patients are decreased by
antipsychotics. If corroborated to (iv), (v), and (vi), this might
provide a further connecting lead to the effects of IL-6 in NED.
We propose that the lines of evidence (i)–(vii) make it reason-
able to think that there is a real neural trait in PCa, and most
notably in NED PCa, that should better be explored mechanisti-
cally. The phenomenon of cancer displaying neural differentiation
has been previously reported for melanoma [see Ref. (198, 199)
and the references therein]. Along the same chain of reason-
ing, brain metastases of both HER2 and triple-negative breast
cancer have recently been found to switch to a neuronal- and
glial-like GABA-ergic phenotype as compared to their primary
tumor counterparts (200). However, both melanocytes and mam-
mary epithelial cells have a completely different developmental
origin from normal and PCa NE cells [reviewed in Ref. (198, 199,
201)]. True neural differentiation of PCa, if properly explored,
would thus open a fascinating view onto the biology of malignant
tumors undergoing NED, neural differentiation, or a mixture of
the two.
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